Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Skin cancer, melanoma
Results 1-25 of 210 for your search:
Start Over
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: 12PLK02, NCI-2013-01697, NCT01856023
Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571
Neurotropic Melanoma of the Head and Neck
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TROG 08.09, NCI-2015-00466, 2009/039, ACTRN12610000478011, NCT00975520
Hypofractionated or Single Dose Image-Guided Radiation Therapy in Treating Patients with Metastatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 10-154, NCI-2010-02150, NCT01223248
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients with High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E1609, NCI-2011-02649, CDR0000692568, ECOG-E1609, NCT01274338
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 103A-301, NCI-2012-01351, NCT01546571
BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO27826, NCI-2012-03085, 2011-004011-24, G027826, NCT01667419
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162A2301, NCI-2013-01413, 2012-003593-51, NCT01763164
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162B2301, NCI-2013-01414, NCT01909453
Pembrolizumab (MK-3475) With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20110265, NCI-2015-00094, 2014-000185-22, NCT02263508
PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
Phase: Phase III
Type: Treatment
Age: 15 and over
Trial IDs: CA209-238, NCI-2015-00460, 2014-002351-26, NCT02388906
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Phase: Phase III
Type: Treatment
Age: 18 to 95
Trial IDs: 20120166, NCI-2014-01975, NCT02147951
Calcitriol and Temozolomide in Treating Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 05M1, NCI-2011-00490, NU-0310-093, SPRI-NU-05M1, NCT00301067
Decitabine, Temozolomide, and Panobinostat In Treating Patients with Treatment-Resistant Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 200807728, NCI-2010-01488, 07080150, NCT00925132
Genetically Modified T Cells, Aldesleukin, and Combination Chemotherapy in Treating Patients with Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0013, NCI-2013-01468, 1004-1036, 110013, 344344, P10648, RD-10-IV-02, NCT01218867
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP 01611, NCI-2014-01584, UPCC 01611, NCT01350401
Recombinant Interleukin-15 After Chemotherapy and Tumor Infiltrating Lymphocyte Transfer in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0170, NCI-2013-01492, P10798, NCT01369888
Ipilimumab, Combination Chemotherapy, and Biological Therapy in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2011-0073, NCI-2011-02768, NCT01409174
Stereotactic Radiosurgery and Ipilimumab in Treating Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 814393, NCI-2012-00749, UPCC 06611, NCT01497808
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2110, NCI-2012-00964, 2011-005875-17, NCT01543698
Leflunomide and Vemurafenib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-088, NCI-2014-00593, NCT01611675
Start Over